Ethicon, Inc., part of the Johnson & Johnson family, is acquiring robotic technology developer Auris Health, Inc. for about $3.4 billion in cash. With its current focus on lung cancer, Auris Health has an FDA-cleared platform for bronchoscopic diagnostic and therapeutic procedures.
“In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” said Ashley McEvoy, executive vice president, worldwide chairman, medical devices, at Johnson & Johnson in a press release. “We believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”
The deal also compliments J&J’s acquisition of Orthotaxy’s robotic technology for orthopaedics, which occurred in February 2018, as well as its development of the Verb Surgical Platform (a partnership between J&J and Verily, formerly Google Life Sciences).
The transaction is expected to close by the end of Q2 this year.